Association of uric acid with risk factors for chronic kidney disease and metabolic syndrome in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 32, Issue 5, 2010, Pages 270-277

  Seki, Shingo ^a   Tsutsui, Kensuke ^a   Fujii, Takurou ^a   Yamazaki, Kouji ^a   Anzawa, Ryuko ^a   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Gender difference; Hypertension; Metabolic syndrome; Uric acid

Indexed keywords

CREATININE; GLUCOSE; TRIACYLGLYCEROL; URIC ACID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERURICEMIA; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RISK FACTOR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGE; AGED; BLOOD; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; HYPERTENSION; KIDNEY; KIDNEY DISEASES; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHRONIC DISEASE; CREATININE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; URIC ACID;

EID: 77955076214     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641960903265220     Document Type: Article

References (28)

1. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41:1183-1190.
2. Yamamoto Y, Matsubara K, Igawa G, Kaetsu Y, Sugihara S, Matsuura T, Ando F, Hamada T, Ogino K, Igawa O, Shigemasa C, Hisatome I. Status of uric acid management in hypertensive subjects. Hypertens Res 2007; 30:549-554
3. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
4. -2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25: 105-1187.
5. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.
6. Fang J, Michael H, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow up study, 1971-1992. JAMA 2000;283: 2404-2410.
7. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relationship between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study. Hypertension 2000;36:1072-1078.
8. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, de Faire U, Ibsen H, Oparil S, Wedel H, Dahlof B. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International 2004;65:1041-1049.
9. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006;47:195-202.
10. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MB. Uric acid is a risk factor for myocardial infarction and stroke. The Rotterdam Study. Stroke 2006;37:1503-1507. (Pubitemid 44305733)
11. Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon B, Jinnah HA. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007;69:1418-1423. (Pubitemid 47511463)
12. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
13. Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney International 2004;65:386-392.
14. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterio Thromb Vasc Biol 2005;25:1038-1044.
15. Tamba S, Nishizawa H, Funahashi T, Okauchi Y, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y. Relationship between the surum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Inter Med 2008;47:1175-1180.
16. Kobayashi J, Nishimura K, Matoba M, Maekawa N, Mabuchi H. Generation and gender differences in the components of contributing to the diagnosis of the metabolic syndrome according to the Japanese criteria. Circ J 2007;71:1734-1737.
17. Devereux RB, Alonso DR, Lutas EM, Gttlieb GJ, Campo E, Sachs I. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
18. Anker S, Doehner W, Rauchaus M, Sharma R, Francis D, Knosalla C. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and haemodynamic staging. Circulation 2001:104:2407-2411.
19. Hakoda M, Masunari N, Yamada M, Fujiwara S, Suzuki G, Kodama K, Kasagi F. Serum uric acid concentration as a risk factor for cardiovascular mortality: A long term cohort study of atomic bomb survivorsa. J Rheumatol 2005;32:906-912.
20. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA. Uric acid and the development of hypertension. The Norma-tive Aging Study. Hypertension 2006;48:1031-1036.
21. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJS, Anker SD, Hambre-cht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuri-cemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624.
22. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, Igawa O, Shigemasa C, Hisatome I. Status of endot-helial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005;96:1576-1578.
23. Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Endo H, Johnson RJ. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006;17:1791-1795.
24. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300:924-932.
25. Seki S, Tsurusaki T, Kasai T, Taniguchi I, Mochizuki S, Yoshimura M. Clinical significance of B-type natriureitic peptide in the assessment of untreated hypertension. Circ J 2008;72:770-777.
26. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-1106.
27. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q. Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-997.
28. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-3011.